In vitro, multiple myeloma cells don’t have the same sensitivity to BAN-induced proteasome inhibition and apoptosis compared to normal cells because it inhibits the NFκB survival pathway, which is more utilized by myeloma cells. This evidence concerns the gene NFKB1 and plasma cell myeloma.